Opportunities and challenges in developing relevant animal models for Alzheimer's disease

Ageing Research Reviews

Volumn 26, Issue , 2016, Pages 112-114

  De Felice, Fernanda G ^a,b   Munoz, Douglas P ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Animal models; Non human primates

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL MODEL; CANINE MODEL; CELL CULTURE; COGNITIVE DEFECT; DISEASE COURSE; MOUSE MODEL; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIMATE; RABBIT MODEL; REVIEW; TAUOPATHY; TRANSGENIC RAT; ANIMAL; BEHAVIORAL RESEARCH; DISEASE MODEL; HUMAN; PROCEDURES; PSYCHOLOGY; TRANSLATIONAL RESEARCH;

ALZHEIMER DISEASE; ANIMALS; BEHAVIORAL RESEARCH; DISEASE MODELS, ANIMAL; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84957059902     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2016.01.006     Document Type: Review

References (28)

1. Cai Y., Xiong K., Zhang X.M., Cai H., Luo X.G., Feng J.C., Clough R.W., Struble R.G., Patrylo P.R., Chu Y., Kordower J.H., Yan X.X. beta-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and beta-amyloid accumulation. Eur. J. Neurosci. 2010, 32:1223-1238.
2. Cohen R.M., Rezai-Zadeh K., Weitz T.M., Rentsendorj A., Gate D., Spivak I., Bholat Y., Vasilevko V., Glabe C.G., Breunig J.J., Rakic P., Davtyan H., Agadjanyan M.G., Kepe V., Barrio J.R., Bannykh S., Szekely C.A., Pechnick R.N., Town T. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss. J. Neurosci. 2013, 33:6245-6256.
3. Cummings J.L., Morstorf T., Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's Res. Ther. 2014, 6:37.
4. Ferreira S.T., Klein W.L. The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol. Learn. Mem. 2011, 96:529-543.
5. Forny-Germano L., Lyra e Silva N.M., Batista A.F., Brito-Moreira J., Gralle M., Boehnke S.E., Coe B.C., Lablans A., Marques S.A., Martinez A.M., Klein W.L., Houzel J.C., Ferreira S.T., Munoz D.P., De Felice F.G. Alzheimer's disease-like pathology induced by amyloid-beta oligomers in nonhuman primates. J. Neurosci. 2014, 34:13629-13643.
6. Geula C., Wu C.K., Saroff D., Lorenzo A., Yuan M., Yankner B.A. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 1998, 4:827-831.
7. Goedert M., Spillantini M.G. A century of Alzheimer's disease. Science 2006, 314:777-781.
8. Gotz J., Ittner L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 2008, 9:532-544.
9. Hara Y., Yuk F., Puri R., Janssen W.G., Rapp P.R., Morrison J.H. Presynaptic mitochondrial morphology in monkey prefrontal cortex correlates with working memory and is improved with estrogen treatment. Proc. Nat. Acad. Sci. U. S. A. 2014, 111(1):486-491.
10. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
11. Heuer E., Rosen R.F., Cintron A., Walker L.C. Nonhuman primate models of Alzheimer-like cerebral proteopathy. Curr. Pharm. Des. 2012, 18:1159-1169.
12. Klyubin I., Walsh D.M., Lemere C.A., Cullen W.K., Shankar G.M., Betts V., Spooner E.T., Jiang L., Anwyl R., Selkoe D.J., Rowan M.J. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 2005, 11:556-561.
13. LaFerla F.M., Green K.N. Animal models of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2.
14. LaFerla F.M., Oddo S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol. Med. 2005, 11:170-176.
15. Leung E., Guo L., Bu J., Maloof M., El Khoury J., Geula C. Microglia activation mediates fibrillar amyloid-beta toxicity in the aged primate cortex. Neurobiol. Aging 2011, 32:387-397.
16. Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., Wang L., Blesch A., Kim A., Conner J.M., Rockenstein E., Chao M.V., Koo E.H., Geschwind D., Masliah E., Chiba A.A., Tuszynski M.H. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 2009, 15:331-337.
17. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
18. Oikawa N., Kimura N., Yanagisawa K. Alzheimer-type tau pathology in advanced aged nonhuman primate brains harboring substantial amyloid deposition. Brain Res. 2010, 1315:137-149.
19. Podlisny M.B., Tolan D.R., Selkoe D.J. Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease. Am. J. Pathol. 1991, 138:1423-1435.
20. Quinn J.F., Raman R., Thomas R.G., Yurko-Mauro K., Nelson E.B., Van Dyck C., Galvin J.E., Emond J., Jack C.R., Weiner M., Shinto L., Aisen P.S. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010, 304:1903-1911.
21. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., Younkin S., Younkin L., Schiff R., Weksler M.E. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 2009, 30:1728-1736.
22. Roher A.E., Kuo Y.M., Potter P.E., Emmerling M.R., Durham R.A., Walker D.G., Sue L.I., Honer W.G., Beach T.G. Cortical cholinergic denervation elicits vascular Abeta deposition. Ann. N. Y. Acad. Sci. 2000, 903:366-373.
23. Sarasa M., Pesini P. Natural non-trasgenic animal models for research in Alzheimer's disease. Curr. Alzheimer Res. 2009, 6(2):171-178.
24. Selkoe D.J. Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 2011, 17:1060-1065.
25. Studzinski C.M., Araujo J.A., Milgram N.W. The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:489-498.
26. Viola K.L., Klein W.L. Amyloid beta oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015, 129:183-206.
27. Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., Lee V.M. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
28. Yu Y.J., Atwal J.K., Zhang Y., Tong R.K., Wildsmith K.R., Tan C., Bien-Ly N., Hersom M., Maloney J.A., Meilandt W.J., Bumbaca D., Gadkar K., Hoyte K., Luk W., Lu Y., Ernst J.A., Scearce-Levie K., Couch J.A., Dennis M.S., Watts R.J. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci. Transl. Med. 2014, 6. 261ra154.